| Date | Title | Description |
| 13.05.2024 | Allogene Therapeutics Announces Pricing of $110 million Offering of Common Stock | SOUTH SAN FRANCISCO, Calif., May 13, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune ... |
| 13.05.2024 | Allogene Therapeutics Announces Pricing of $110 million Offering of Common Stock | - |
| 12.03.2024 | Allogene Therapeutics and Arbor Biotechnologies Announce Global Gene Editing Licensing Agreement to Support Advancement of Next-Generation Allogeneic CAR T Platform in Autoimmune Disease | - |
| 05.03.2024 | Allogene Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update | - |
| 12.01.2022 | Allogene Therapeutics : JPM Presentation 2022 | The Next Revolution in Cell Therapy
Leading Today, Defining Tomorrow
January 2022
Legal Disclaimers
To the extent statements contained in this Presentation are not descriptions of historical facts regarding Allogene Therapeutics, Inc. (&quo... |
| 14.12.2021 | Allogene Therapeutics : ASH 2021 Conference Call Presentation | The Potential Innovation of Allogeneic CAR T Therapy in Hematologic Cancers
American Society of Hematology (ASH) December 13, 2021
Legal Disclaimers
To the extent statements contained in this Presentation are not descriptions of historical ... |
| 15.11.2021 | Allogene Therapeutics : Corporate Presentation - November 2021 | The Next Revolution in Cell Therapy
Leading Today, Creating Tomorrow
November 2021
Legal Disclaimers
To the extent statements contained in this Presentation are not descriptions of historical facts regarding Allogene Therapeutics, Inc. (&qu... |
| 10.08.2021 | Bringing immuno-oncology cell therapies to the masses – are we (nearly) there yet? | |
| 10.02.2021 | Allogene partner Notch snags $85M for renewable cell therapies | Several companies are working to make cell therapies cheaper and more widely available by making them from donor cells rather than patients' own cells. Notch Therapeutics is going one step further with cancer treatments based on stem cells ... |
| 10.02.2021 | Allogene partner Notch snags $85M for renewable cell therapies
W h i t e p a p e r
Vital Precision for Cost Reduction, QA, and Regulatory Compliance | Several companies are working to make cell therapies cheaper and more widely available by making them from donor cells rather than patients' own cells. Notch Therapeutics is going one step further with cancer treatments based on stem cells ... |
| 19.01.2021 | Allogene Therapeutics : J.P. Morgan Conference Presentation - January 2021 | The Next Revolution in Cell Therapy
Leading Today, Creating Tomorrow
39th Annual J.P. Morgan Healthcare Conference
January 2021
Legal Disclaimers
To the extent statements contained in this Presentation are not descriptions of historical fac... |
| 19.01.2021 | ALLOGENE THERAPEUTICS, INC.
Allogene Therapeutics : J.P. Morgan Conference Presentation - January 2021 | The Next Revolution in Cell Therapy
Leading Today, Creating Tomorrow
39th Annual J.P. Morgan Healthcare Conference
January 2021
Legal Disclaimers
To the extent statements contained in this Presentation are not descriptions of historical fac... |
| 15.01.2021 | Allogene Therapeutics : J.P. Morgan Conference Presentation - January 2021 | The Next Revolution in Cell Therapy
Leading Today, Creating Tomorrow
39th Annual J.P. Morgan Healthcare Conference
January 2021
Legal Disclaimers
To the extent statements contained in this Presentation are not descriptions of historical fac... |
| 15.01.2021 | ALLOGENE THERAPEUTICS, INC.
Allogene Therapeutics : J.P. Morgan Conference Presentation - January 2021 | The Next Revolution in Cell Therapy
Leading Today, Creating Tomorrow
39th Annual J.P. Morgan Healthcare Conference
January 2021
Legal Disclaimers
To the extent statements contained in this Presentation are not descriptions of historical fac... |
| 13.01.2021 | ALLOGENE THERAPEUTICS, INC.
Allogene Therapeutics : Corporate Presentation January 2021 | The Next Revolution in Cell Therapy
Leading Today, Creating Tomorrow
January 2021
Legal Disclaimers
To the extent statements contained in this Presentation are not descriptions of historical facts regarding Allogene Therapeutics, Inc. (&quo... |
| 12.01.2021 | Allogene Therapeutics : Corporate Presentation January 2021 | The Next Revolution in Cell Therapy
Leading Today, Creating Tomorrow
January 2021
Legal Disclaimers
To the extent statements contained in this Presentation are not descriptions of historical facts regarding Allogene Therapeutics, Inc. (&quo... |
| 20.10.2020 | MD Anderson establishes new $50M+ biotech fund to choose the next promising cancer therapies | Researchers at MD Anderson have a new partner to help them get early-stage programs into the clinic.
In conjunction with The Focus Fund, MD Anderson is launching the Cancer Focus Fund to advance investigational cancer... |
| 15.01.2020 | Astellas partners with Adaptimmune in latest move into cell therapy | Most TCRs that have been developed are HLA-restricted, meaning they can only be used in patients with particular genetic profiles. Meanwhile, both FDA-approved CAR-Ts, Novartis’ Kymriah (tisagenlecleucel) and Gilead Sciences’ Yescarta (axic... |
| 05.11.2019 | Notch Therapeutics Announces R&D Collaboration with Allogene worth up to $283M per Target | SOUTH SAN FRANCISCO, Calif. and TORONTO — Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer, and Notch Therapeutics Inc., an i... |
| 28.01.2019 | Allogene gets FDA go-ahead to start ‘off-the-shelf’ CAR-T study in lymphoma | ALLO-501 targets CD19, an antigen widely expressed in B-cell non-Hodgkin’s lymphomas like DLBCL and FL. The CAR-T will be administered following a lymphodepletion regimen of the chemotherapy drugs fludarabine and cyclophosphamide, which are... |
| 07.12.2018 | Moderna raises more than $600M in biggest-ever biotech IPO | Moderna had raised $500 million in a Series G financing round of private equity financing that gave it a $7 billion valuation. As of Sept. 30, it had raised $1.8 billion in equity and $800 million through partnerships with companies like As... |
| 04.12.2018 | Allogene ‘off-the-shelf’ CAR-T for leukemia shows high response rate at ASH | Allogene made headlines earlier this year when it launched in April with a $300 million Series A round of venture capital funding from several firms and Kite Pharma founders Arie Belldegrun and David Chang at the helm. Five months later, th... |
| 12.11.2018 | Moderna Therapeutics seeks $500M for IPO | The filing comes nine months after the company closed a $500 million Series G round of private equity financing that gave the company a $7 billion valuation. As of Sept. 30, the company raised $1.8 billion in equity and $800 million through... |
| 09.11.2018 | Big dreams, big pay and a big IPO: Moderna lights up a pitch for a record $500M biotech IPO | Moderna’s executive team never does anything small — or non-controversial.
They’ve built a biotech unicorn with a $7.5 billion valuation without anything close to pivotal data to back up their ambitions in messenger R... |
| 04.11.2018 | Life sciences VC investment trends similar to tech, but there are differences | There are some similar trends in the life sciences market versus technology overall, but there are some differences in underlying drivers, said Menlo Park Ventures life sciences investor Greg Yap, in an email. “Round sizes have continued to... |
| 24.10.2018 | Какие стартапы борются с онкологическими заболеваниями за рубежом и в России Статьи редакции | Подборка наиболее крупных по размеру вложений компаний.
26 26 комментариев
3928 просмотров
Список зарубежных стартапов составлен на основе рейтинга сайта Medical Startups. Компании распределены исходя из общей суммы инвестированных в них ср... |
| 11.10.2018 | Allogene Therapeutics Raises $324 Million in IPO as Shares Soar | - |
| 14.09.2018 | ‘Off-the-shelf’ CAR-T company Allogene files for $100M IPO | On Sept. 7, the company said it raised a $120 million private financing from several funds. Allogene was launched in April with a $300 million Series A funding round. Shortly before Allogene’s $120 million raise, liquid biopsy firm Guardant... |
| 07.09.2018 | Allogene raises $120M for ‘off-the-shelf’ CAR-T development | The firm – of which Kite founders David Chang and Arie Belldegrun respectively serve as CEO and executive chairman – is developing allogeneic, or “off-the-shelf” CAR-T therapies. Allogeneic CAR-Ts are made with donor cells designed to be us... |
| 07.09.2018 | Daily funding roundup - September 7th, 2018 | Scipher Medicine raised $10M led by Khosla Ventures; Allogen Therapeutics raised $120M
Pani Systems: Based in Austin, Pani Systems is building smart-home appliances that help utilities and consumers measure, monitor, and repurpose water. Fu... |
| 06.09.2018 | Allogene Therapeutics Completes a $120 Million Private Financing | - |
| - | Allogeneic CAR T products: The next frontier in cancer treatment | Innovation in the fight against cancer has come in great waves. The first came with the discovery of cytotoxic chemotherapy and engulfed most of the 20th century. But fundamental discoveries in blood cancer gave way to increasingly sophisti... |
| - | Life sciences VC investment trends similar to tech, but there are differences | Venture capital investing has already reached a 10-year high in 2018, according to a report last week. However, while investment trends in life sciences have been similar to those in technology generally, a venture capital investor speciali... |
| - | Allogene ‘off-the-shelf’ CAR-T for leukemia shows high response rate at ASH | A company developing off-the-shelf CAR-T cell therapies that went from startup phase to an initial public offering in the space of a few months earlier this year made its clinical data debut at the American Society of Hematology.
South San ... |
| - | Moderna raises more than $600M in biggest-ever biotech IPO | A biotechnology company that sought to pull off the largest ever initial public offering in its sector has fulfilled its wish.
Cambridge, Massachusetts-based Moderna announced Thursday that the pricing of its initial public offering was $60... |
| - | Allogene raises $120M for ‘off-the-shelf’ CAR-T development | A company started by former executives from Kite Pharma has raised $120 million to develop the next generation of CAR-T therapies.
South San Francisco, California-based Allogene Therapeutics said the private financing was led by Perceptive ... |
| - | Beyond the myths of scientific breakthroughs | There are two great myths in science. The first is of the lone inventor, emerging from the basement laboratory with an “ah ha” moment as they solve the mysteries of life. The second is that drug development proceeds down a straight path fro... |
| - | Astellas partners with Adaptimmune in latest move into cell therapy | Although the two CAR-T cell therapies that the Food and Drug Administration approved in 2017 remain the only ones on the market, a number of companies have busied themselves with their own programs, developing their own capabilities and als... |
| - | Moderna Therapeutics seeks $500M for IPO | A company developing drugs that target the messenger RNA pathway has filed for what could be the largest-ever initial public offering for a biotech company.
In an S-1 filing with the Securities and Exchange Commission Friday, Cambridge, Mas... |
| - | Allogene gets FDA go-ahead to start ‘off-the-shelf’ CAR-T study in lymphoma | A company founded by former executives of Kite Pharma will start a Phase I study of a so-called “off-the-shelf” CAR-T therapy in the first half of this year, now that it has the Food and Drug Administration’s authorization to do so.
South S... |
| - | New Hope for Patients as Science Advances in Allogeneic CAR T | Five years ago, the FDA approval of autologous CAR T therapy for the treatment of certain late-stage blood cancers started a revolution. This was a major step forward in cancer treatment and life changing for many patients who were running ... |
| - | ‘Off-the-shelf’ CAR-T company Allogene files for $100M IPO | With the ink barely dry on its recent private financing, and only slightly drier on its initial big venture capital funding round, a company developing so-called “off-the-shelf” CAR-T therapies has already filed to go public.
South San Fran... |
